224 related articles for article (PubMed ID: 29717697)
1. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016.
Mentzer D; Oberle D; Keller-Stanislawski B
Euro Surveill; 2018 Apr; 23(17):. PubMed ID: 29717697
[TBL] [Abstract][Full Text] [Related]
2. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.
De Serres G; Billard MN; Gariépy MC; Rouleau I; Toth E; Landry M; Boulianne N; Gagné H; Gilca V; Deceuninck G; Ouakki M; Skowronski DM
Vaccine; 2018 Dec; 36(52):8039-8046. PubMed ID: 30467063
[TBL] [Abstract][Full Text] [Related]
3. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
[TBL] [Abstract][Full Text] [Related]
4. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
Carter NJ
BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
[TBL] [Abstract][Full Text] [Related]
5. Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials.
Zafack JG; Bureau A; Skowronski DM; De Serres G
BMJ Open; 2019 May; 9(5):e026953. PubMed ID: 31110098
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
Biolchi A; Tomei S; Santini L; Welsch JA; Toneatto D; Gaitatzis N; Bai X; Borrow R; Giuliani MM; Mori E; Pizza M
Hum Vaccin Immunother; 2019; 15(3):725-731. PubMed ID: 30352000
[TBL] [Abstract][Full Text] [Related]
7. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial.
Martinón-Torres F; Safadi MAP; Martinez AC; Marquez PI; Torres JCT; Weckx LY; Moreira ED; Mensi I; Calabresi M; Toneatto D
Vaccine; 2017 Jun; 35(28):3548-3557. PubMed ID: 28533054
[TBL] [Abstract][Full Text] [Related]
8. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
Martin NG; Snape MD
Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957
[TBL] [Abstract][Full Text] [Related]
9. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
Esposito S; Principi N
Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB).
Marshall GS; Abbing-Karahagopian V; Marshall HS; Cenci S; Conway JH; Occhipinti E; Bekkat-Berkani R; Banzhoff A; Sohn WY
Expert Rev Vaccines; 2023; 22(1):530-544. PubMed ID: 37278390
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I).
Prymula R; Esposito S; Zuccotti GV; Xie F; Toneatto D; Kohl I; Dull PM
Hum Vaccin Immunother; 2014; 10(7):1993-2004. PubMed ID: 25424809
[TBL] [Abstract][Full Text] [Related]
12. Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017.
Masuka JT; Khoza S
BMC Public Health; 2019 Aug; 19(1):1166. PubMed ID: 31455314
[TBL] [Abstract][Full Text] [Related]
13. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
[No Abstract] [Full Text] [Related]
14. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
[TBL] [Abstract][Full Text] [Related]
15. Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study.
Langley JM; MacDougall DM; Halperin BA; Swain A; Halperin SA; Top KA; McNeil SA; MacKinnon-Cameron D; Marty K; De Serres G; Dubé E; Bettinger JA
Vaccine; 2016 Jul; 34(34):4046-9. PubMed ID: 27302338
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study.
Chiu NC; Huang LM; Willemsen A; Bhusal C; Arora AK; Reynoso Mojares Z; Toneatto D
Hum Vaccin Immunother; 2018 May; 14(5):1075-1083. PubMed ID: 29337653
[TBL] [Abstract][Full Text] [Related]
17. Group B meningococcal vaccine science and policy.
Drysdale SB; Pollard AJ
J Infect; 2015 Jun; 71 Suppl 1():S15-20. PubMed ID: 25917798
[TBL] [Abstract][Full Text] [Related]
18. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.
Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D
Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of Meningococcus B vaccine in patients with chronical medical conditions (CMC).
Nicolosi L; Rizzo C; Gattinara GC; Mirante N; Bellelli E; Bianchini C; Pansini V; Villani A
Ital J Pediatr; 2019 Oct; 45(1):133. PubMed ID: 31666107
[TBL] [Abstract][Full Text] [Related]
20. Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018.
Perez-Vilar S; Dores GM; Marquez PL; Ng CS; Cano MV; Rastogi A; Lee L; Su JR; Duffy J
Vaccine; 2022 Jan; 40(2):247-254. PubMed ID: 34887130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
